Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : EMA Recommends Change To Product Information For Remdesivir To Include Sinus Bradycardia As Adverse Reaction

06/11/2021 | 12:27pm EDT

June 11 (Reuters) - European Medicines Agency:

* EMA SAYS PRAC RECOMMENDED CHANGE TO PRODUCT INFORMATION FOR REMDESIVIR TO INCLUDE SINUS BRADYCARDIA AS ADVERSE REACTION OF UNKNOWN FREQUENCY FOR MEDICINE

* EMA SAYS PRAC CONCLUDED THAT A CAUSAL RELATIONSHIP BETWEEN USE OF REMDESIVIR AND ADVERSE EVENT OF BRADYCARDIA IS AT LEAST A REASONABLE POSSIBILITY

* EMA SAYS DHPC IS INTENDED TO INFORM HEALTHCARE PROFESSIONALS ABOUT OUTCOME OF A SIGNAL PROCEDURE AND NEW RECOMMENDATIONS FOR USE OF XELJANZ

* EMA SAYS PRAC ADVISING XELJANZ BE USED IN PATIENTS OVER 65 YRS, CURRENT/PAST SMOKERS, OTHER CARDIOVASCULAR RISK FACTORS IF NO SUITABLE ALTERNATIVE AVAILABLE Further company coverage:


ę Reuters 2021
All news about GILEAD SCIENCES, INC.
10:32aGILEAD SCIENCESá : Kite Partners With Shoreline Biosciences to Develop Cancer Th..
MT
09:06aGILEAD SCIENCESá : Kite and Shoreline Biosciences Enter Into Strategic Partnersh..
BU
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICSá : Set for $25 Million Milestone Payment from Gilead After I..
MT
06/15GILEAD SCIENCESá : Jounce Therapeutics Achieves First Milestone in Exclusive Lic..
AQ
06/15Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
DJ
06/14INSIDER TRENDS : Gilead Sciences Insider Converts Option/Derivative Security to ..
MT
06/14GILEAD SCIENCESá : University of Cambridge - Longer-term Data for Kite's Yescart..
AQ
06/14GILEAD SCIENCES'á : Lymphatic System Cancer Drug Shows 94% Response Rate in Foll..
MT
More news
Financials (USD)
Sales 2021 24 680 M - -
Net income 2021 6 885 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 12,7x
Yield 2021 4,17%
Capitalization 84 306 M 84 306 M -
EV / Sales 2021 4,31x
EV / Sales 2022 4,26x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 75,15 $
Last Close Price 67,33 $
Spread / Highest target 48,5%
Spread / Average Target 11,6%
Spread / Lowest Target -10,9%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.15.57%84 444
WUXI APPTEC CO., LTD.21.14%62 089
REGENERON PHARMACEUTICALS8.38%54 220
BIONTECH SE150.06%49 234
VERTEX PHARMACEUTICALS-20.67%48 535
BEIGENE, LTD.28.99%30 782